Items without sitelinks

Jump to navigation Jump to search

Showing below up to 50 results starting with #5,701.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Methods (Q7979)
  2. Introduction (Q7978)
  3. Reference 19 in the bibliography for DOI: 10.7326/m20-0504 (Q7977)
  4. Reference 18 in the bibliography for DOI: 10.7326/m20-0504 (Q7976)
  5. Reference 17 in the bibliography for DOI: 10.7326/m20-0504 (Q7975)
  6. Reference 16 in the bibliography for DOI: 10.7326/m20-0504 (Q7974)
  7. Reference 15 in the bibliography for DOI: 10.7326/m20-0504 (Q7973)
  8. Reference 14 in the bibliography for DOI: 10.7326/m20-0504 (Q7972)
  9. Reference 13 in the bibliography for DOI: 10.7326/m20-0504 (Q7971)
  10. Reference 12 in the bibliography for DOI: 10.7326/m20-0504 (Q7970)
  11. Reference 11 in the bibliography for DOI: 10.7326/m20-0504 (Q7969)
  12. Reference 10 in the bibliography for DOI: 10.7326/m20-0504 (Q7968)
  13. Reference 9 in the bibliography for DOI: 10.7326/m20-0504 (Q7967)
  14. Reference 8 in the bibliography for DOI: 10.7326/m20-0504 (Q7966)
  15. Reference 7 in the bibliography for DOI: 10.7326/m20-0504 (Q7965)
  16. Reference 6 in the bibliography for DOI: 10.7326/m20-0504 (Q7964)
  17. Reference 5 in the bibliography for DOI: 10.7326/m20-0504 (Q7963)
  18. Reference 4 in the bibliography for DOI: 10.7326/m20-0504 (Q7962)
  19. Reference 3 in the bibliography for DOI: 10.7326/m20-0504 (Q7961)
  20. Reference 2 in the bibliography for DOI: 10.7326/m20-0504 (Q7960)
  21. Reference 1 in the bibliography for DOI: 10.7326/m20-0504 (Q7959)
  22. 5th paragraph(s) in DISCUSSION section (From DOI: 10.7326/m20-0504) (Q7958)
  23. 4th paragraph(s) in DISCUSSION section (From DOI: 10.7326/m20-0504) (Q7957)
  24. 3rd paragraph(s) in DISCUSSION section (From DOI: 10.7326/m20-0504) (Q7956)
  25. 2nd paragraph(s) in DISCUSSION section (From DOI: 10.7326/m20-0504) (Q7955)
  26. 1st paragraph(s) in DISCUSSION section (From DOI: 10.7326/m20-0504) (Q7954)
  27. 6th paragraph(s) in RESULTS section (From DOI: 10.7326/m20-0504) (Q7953)
  28. 5th paragraph(s) in RESULTS section (From DOI: 10.7326/m20-0504) (Q7952)
  29. 4th paragraph(s) in RESULTS section (From DOI: 10.7326/m20-0504) (Q7951)
  30. 3rd paragraph(s) in RESULTS section (From DOI: 10.7326/m20-0504) (Q7950)
  31. 2nd paragraph(s) in RESULTS section (From DOI: 10.7326/m20-0504) (Q7949)
  32. 1st paragraph(s) in RESULTS section (From DOI: 10.7326/m20-0504) (Q7948)
  33. 1st paragraph(s) in METHODS: Role of the Funding Source subsection (From DOI: 10.7326/m20-0504) (Q7947)
  34. 3rd paragraph(s) in METHODS: Statistical Analysis subsection (From DOI: 10.7326/m20-0504) (Q7946)
  35. 2nd paragraph(s) in METHODS: Statistical Analysis subsection (From DOI: 10.7326/m20-0504) (Q7945)
  36. 1st paragraph(s) in METHODS: Statistical Analysis subsection (From DOI: 10.7326/m20-0504) (Q7944)
  37. 2nd paragraph(s) in METHODS: Data Collection subsection (From DOI: 10.7326/m20-0504) (Q7943)
  38. 1st paragraph(s) in METHODS: Data Collection subsection (From DOI: 10.7326/m20-0504) (Q7942)
  39. 3rd paragraph(s) in Introduction (From DOI: 10.7326/m20-0504) (Q7941)
  40. 2nd paragraph(s) in Introduction (From DOI: 10.7326/m20-0504) (Q7940)
  41. 1st paragraph(s) in Introduction (From DOI: 10.7326/m20-0504) (Q7939)
  42. Appendix (From DOI: 10.7326/m20-0504) (Q7938)
  43. Full Bibliography (From DOI: 10.7326/m20-0504) (Q7937)
  44. Conflicts of Interest (From DOI: 10.7326/m20-0504) (Q7936)
  45. Funding (From DOI: 10.7326/m20-0504) (Q7935)
  46. Acknowledgments (From DOI: 10.7326/m20-0504) (Q7934)
  47. Author Contributions (From DOI: 10.7326/m20-0504) (Q7933)
  48. Figure 3 - Proportion of known symptomatic SARS-CoV-2 infections that have yet to develop symptoms, by number of days since infection, using bootstrapped estimates from a log-normal accelerated failure time model. (From DOI: 10.7326/m20-0504) (Q7932)
  49. Figure 2 - Cumulative distribution function of the COVID-19 incubation period estimate from the log-normal model. (From DOI: 10.7326/m20-0504) (Q7931)
  50. Figure 1 - SARS-CoV-2 exposure (blue), symptom onset (red), and case detection (green) times for 181 confirmed cases. (From DOI: 10.7326/m20-0504) (Q7930)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)